Oligosaccharide analysis in urine by MALDI-TOF mass spectrometry for the diagnosis of lysosomal storage diseases

Clinical Chemistry

Volumn 59, Issue 9, 2013, Pages 1357-1368

  Xia, Baoyun ^a   Asif, Ghazia ^a   Arthur, Leonard ^a   Pervaiz, Muhammad A ^a   Li, Xueli ^a   Liu, Renpeng ^a   Cummings, Richard D ^a   He, Miao ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOCONJUGATE; OLIGOSACCHARIDE;

ARTICLE; ASPARTYLGLYCOSAMINURIA; BIOACCUMULATION; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; GM1 GANGLIOSIDOSIS; HUMAN; LYSOSOME STORAGE DISEASE; MACROMOLECULE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUCOLIPIDOSIS TYPE 1; MUCOLIPIDOSIS TYPE 3; SCREENING TEST; SENSITIVITY AND SPECIFICITY; THIN LAYER CHROMATOGRAPHY; URINALYSIS;

ADOLESCENT; ASPARTYLGLUCOSAMINURIA; CHILD; CHILD, PRESCHOOL; FEMALE; FUCOSIDOSIS; GANGLIOSIDOSES, GM2; GANGLIOSIDOSIS, GM1; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; INFANT, NEWBORN; LYSOSOMAL STORAGE DISEASES; MALE; MANNOSIDASE DEFICIENCY DISEASES; MUCOLIPIDOSES; OLIGOSACCHARIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84883314366     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.201053     Document Type: Article

References (31)

1. Honda S. High-performance liquid chromatography of mono- and oligosaccharides. Anal Biochem 1984;140:1- 47.
2. Sowell J, Wood T. Towards a selected reaction monitoring mass spectrometry fingerprint approach for the screening of oligosaccharidoses. Anal Chim Acta 2011;686:102- 6.
3. Anumula KR. High-sensitivity and high-resolution methods for glycoprotein analysis. Anal Biochem 2000;283:17-26.
4. Ramsay SL, Meikle PJ, Hopwood JJ, Clements PR. Profiling oligosaccharidurias by electrospray tandem mass spectrometry: quantifying reducing oligosaccharides. Anal Biochem 2005;345:30-46.
5. Klein A, Lebreton A, Lemoine J, Perini JM, Roussel P, Michalski JC. Identification of urinary oligosaccharides by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Chem 1998;44:2422- 8.
6. Saba JA, Shen X, Jamieson JC, Perreault H. Investigation of different combinations of derivatization, separation methods and electrospray ionization mass spectrometry for standard oligosaccharides and glycans from ovalbumin. J Mass Spectrom 2001;36:563-74.
7. Wada Y, Azadi P, Costello CE, Dell A, Dwek RA, Geyer H, et al. Comparison of the methods for profiling glycoprotein glycans-HUPO Human Disease Glycomics/Proteome Initiative multiinstitutional study. Glycobiology 2007;17:411-22.
8. Guillard M, Morava E, van Delft FL, Hague R, Korner C, Adamowicz M, et al. Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II. Clin Chem 2011; 57:593- 602.
9. Clements PR. Determination of sialylated and neutral oligosaccharides in urine by mass spectrometry. Curr Protoc Hum Genet 2012;72: 17.10.1-14.
10. Asano K, Shindo N, Nakasuji M, Inamori K, Ohta M, Matsushita T, et al. A case of GM1-gangliosidosis type I: glycosphingolipid profiles of urine and transformed lymphocytes and beta-Dgalactosidase activities in peripheral lymphocytes, cultured skin fibroblasts and transformed lymphocytes. Jpn J Exp Med 1990;60:73-9.
11. Aronson NN Jr. Aspartylglycosaminuria: biochemistry and molecular biology. Biochim Biophys Acta 1999;1455:139 -54.
12. Morris C, Heisterkamp N, Groffen J, Williams JC, Mononen I. Chromosomal localization of the human glycoasparaginase gene to 4q32-q33. Hum Genet 1992;88:295-7.
13. Oheda Y, Kotani M, Murata M, Sakuraba H, Kadota Y, Tatano Y, et al. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement. Glycobiology 2006;16: 271-80.
14. Wenger DA, Tarby TJ, Wharton C. Macular cherryred spots and myoclonus with dementia: coexistent neuraminidase and beta-galactosidase deficiencies. Biochem Biophys Res Commun 1978;82: 589-95.
15. Willems PJ, Seo HC, Coucke P, Tonlorenzi R, O'Brien JS. Spectrum of mutations in fucosidosis. Eur J Hum Genet 1999;7:60 -7.
16. Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited diseases. 8th ed. New York: McGraw-Hill; 2001. p 3389-420. Chapter 135.
17. Young SP, Stevens RD, An Y, Chen YT, Millington DS. Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry. Anal Biochem 2003;316:175- 80.
18. Grace ME, Berg A, He GS, Goldberg L, Horowitz M, Grabowski GA. Gaucher disease: heterologous expression of two alleles associated with neuronopathic phenotypes. Am J Hum Genet 1991; 49:646 -55.
19. Zimran A, Gelbart T, Westwood B, Grabowski GA, Beutler E. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet 1991;49:855-9.
20. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-9.
21. Stinchi S, Lullmann-Rauch R, Hartmann D, Coenen R, Beccari T, Orlacchio A, et al. Targeted disruption of the lysosomal alpha-mannosidase gene results in mice resembling a mild form of human alpha-mannosidosis. Hum Mol Genet 1999;8:1365-72.
22. Mynarek M, Tolar J, Albert MH, Escolar ML, Boelens JJ, Cowan MJ, et al. Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. Bone Marrow Transplant 2012;47: 352-9.
23. Abraham D, Daniel P, Dell A, Oates J, Sidebotham R, Winchester B. Structural analysis of the major urinary oligosaccharides in feline alphamannosidosis. Biochem J 1986;233:899 -904.
24. De Gasperi R, Daniel PF, Warren CD. A human lysosomal alpha-mannosidase specific for the core of complex glycans. J Biol Chem 1992;267: 9706-12.
25. Rose DR. Structure, mechanism and inhibition of Golgi α-mannosidase II. Curr Opin Struct Biol 2012;22:558-62.
26. Specola N, Vanier MT, Goutieres F, Mikol J, Aicardi J. The juvenile and chronic forms of GM2 gangliosidosis: clinical and enzymatic heterogeneity. Neurology 1990;40:145-50.
27. Maegawa GH, Stockley T, Tropak M, Banwell B, Blaser S, Kok F, et al. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics 2006;118:e1550-62.
28. Inui K, Grebner EE, Jackson LG, Wenger DA. Juvenile GM2 gangliosidosis (AMB variant): inability to activate hexosaminidase A by activator protein. Am J Hum Genet 1983;35:551- 64.
29. Seyrantepe V, Poupetova H, Froissart R, Zabot MT, Maire I, Pshezhetsky AV. Molecular pathology of NEU1 gene in sialidosis. Hum Mutat 2003; 22:343-52.
30. Caciotti A, Di Rocco M, Filocamo M, Grossi S, Traverso F, d'Azzo A, et al. Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients. J Neurol 2009;256:1911-5.
31. Volker C, De Praeter CM, Hardt B, Breuer W, Kalz-Fuller B, Van Coster RN, Bause E. Processing of N-linked carbohydrate chains in a patient with glucosidase I deficiency (CDG type IIb). Glycobiology 2002;12:473- 83.